-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Reviewing Bone Biologics (OTC:BBLG) and Allied Healthcare Products (NASDAQ:AHPI)
Reviewing Bone Biologics (OTC:BBLG) and Allied Healthcare Products (NASDAQ:AHPI)
Bone Biologics (OTC:BBLG – Get Rating) and Allied Healthcare Products (NASDAQ:AHPI – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.
Profitability
This table compares Bone Biologics and Allied Healthcare Products' net margins, return on equity and return on assets.
Get Bone Biologics alerts:| Net Margins | Return on Equity | Return on Assets | |
| Bone Biologics | N/A | 7,587.33% | 7,258.20% |
| Allied Healthcare Products | -19.82% | -70.44% | -31.16% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Bone Biologics and Allied Healthcare Products, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bone Biologics | 0 | 0 | 1 | 0 | 3.00 |
| Allied Healthcare Products | 0 | 0 | 0 | 0 | N/A |
Risk & Volatility
Bone Biologics has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Allied Healthcare Products has a beta of -2.44, meaning that its share price is 344% less volatile than the S&P 500.
Insider and Institutional Ownership
7.6% of Bone Biologics shares are owned by institutional investors. Comparatively, 4.2% of Allied Healthcare Products shares are owned by institutional investors. 5.1% of Allied Healthcare Products shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Bone Biologics and Allied Healthcare Products' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bone Biologics | N/A | N/A | -$1.61 million | N/A | N/A |
| Allied Healthcare Products | $27.05 million | 0.16 | -$5.36 million | ($1.34) | -0.82 |
Bone Biologics has higher earnings, but lower revenue than Allied Healthcare Products.
Summary
Bone Biologics beats Allied Healthcare Products on 8 of the 10 factors compared between the two stocks.
About Bone Biologics
(Get Rating)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
About Allied Healthcare Products
(Get Rating)
Allied Healthcare Products, Inc. engages in manufacturing respiratory products used in the health care industry in hospitals and alternate site settings, including sub-acute care facilities, home health care and emergency medical care. Its product line includes respiratory care products, medical gas equipment, and emergency medical products. The company was founded in 1979 and is headquartered in St. Louis, MO.
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
Bone Biologics (OTC:BBLG – Get Rating) and Allied Healthcare Products (NASDAQ:AHPI – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.
骨生物(場外交易：BBLG-GET評級)和聯合保健品(納斯達克：AHPI-GET評級)都是小盤醫療公司，但哪種投資更好？我們將根據兩家公司的機構持股、分析師建議、風險、盈利能力、收益、估值和股息的實力進行比較。
Profitability
盈利能力
This table compares Bone Biologics and Allied Healthcare Products' net margins, return on equity and return on assets.
此表比較了骨生物和聯合醫療保健產品的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Bone Biologics | N/A | 7,587.33% | 7,258.20% |
| Allied Healthcare Products | -19.82% | -70.44% | -31.16% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 骨生物製品 | 不適用 | 7,587.33% | 7,258.20% |
| 聯合醫療保健產品 | -19.82% | -70.44% | -31.16% |
Analyst Ratings
分析師評級
This is a summary of recent ratings and recommmendations for Bone Biologics and Allied Healthcare Products, as reported by MarketBeat.
這是MarketBeat報道的骨生物製品和聯合醫療保健產品最近的評級和推薦摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bone Biologics | 0 | 0 | 1 | 0 | 3.00 |
| Allied Healthcare Products | 0 | 0 | 0 | 0 | N/A |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 骨生物製品 | 0 | 0 | 1 | 0 | 3.00 |
| 聯合醫療保健產品 | 0 | 0 | 0 | 0 | 不適用 |
Risk & Volatility
風險與波動性
Bone Biologics has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Allied Healthcare Products has a beta of -2.44, meaning that its share price is 344% less volatile than the S&P 500.
Bone Biologics的貝塔係數為0.24，這意味着其股價的波動性比標準普爾500指數低76%。相比之下，聯合醫療保健產品的貝塔係數為-2.44，這意味着其股價的波動性比標準普爾500指數低344%。
Insider and Institutional Ownership
內部人與機構持股
7.6% of Bone Biologics shares are owned by institutional investors. Comparatively, 4.2% of Allied Healthcare Products shares are owned by institutional investors. 5.1% of Allied Healthcare Products shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
骨生物公司7.6%的股份由機構投資者持有。相比之下，聯合醫療保健產品公司4.2%的股份由機構投資者持有。聯合醫療保健產品公司5.1%的股份由公司內部人士持有。強大的機構持股表明，大型基金管理公司、捐贈基金和對衝基金相信，一隻股票的長期表現將好於大盤。
Earnings & Valuation
收益與估值
This table compares Bone Biologics and Allied Healthcare Products' revenue, earnings per share and valuation.
該表比較了骨生物和聯合保健產品的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bone Biologics | N/A | N/A | -$1.61 million | N/A | N/A |
| Allied Healthcare Products | $27.05 million | 0.16 | -$5.36 million | ($1.34) | -0.82 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 骨生物製品 | 不適用 | 不適用 | -161萬美元 | 不適用 | 不適用 |
| 聯合醫療保健產品 | 2705萬美元 | 0.16 | -536萬元 | ($1.34) | -0.82 |
Bone Biologics has higher earnings, but lower revenue than Allied Healthcare Products.
與聯合醫療保健產品相比，骨生物製藥的收益更高，但收入更低。
Summary
摘要
Bone Biologics beats Allied Healthcare Products on 8 of the 10 factors compared between the two stocks.
骨生物公司在兩隻股票的10個因素中有8個超過了聯合醫療保健產品公司。
About Bone Biologics
關於骨生物製品
(Get Rating)
(獲取評級)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
骨生物公司是一家醫療設備公司，專注於使用重組人蛋白在脊柱融合中進行骨再生。該公司的Nell-1/DBX是一種組合產品，是一種骨刺激重組蛋白，提供對骨再生的靶向特異性控制。該公司正在開發Nell-1/DBX融合器，用於L4-S1一級退行性腰椎間盤疾病骨性成熟患者的脊柱融合手術。該公司的平臺技術在脊柱、整形外科、普通整形外科、整形外科、神經外科、介入放射學和運動醫學等外科專業中具有增強的應用效果。它與加州大學洛杉磯分校技術開發集團簽署了一項許可協議，開發和商業化用於脊柱融合應用的Nell-1。該公司成立於2004年，總部設在馬薩諸塞州伯靈頓。
About Allied Healthcare Products
關於聯合醫療保健產品
(Get Rating)
(獲取評級)
Allied Healthcare Products, Inc. engages in manufacturing respiratory products used in the health care industry in hospitals and alternate site settings, including sub-acute care facilities, home health care and emergency medical care. Its product line includes respiratory care products, medical gas equipment, and emergency medical products. The company was founded in 1979 and is headquartered in St. Louis, MO.
聯合保健產品公司致力於在醫院和備用場所生產用於保健行業的呼吸系統產品，包括亞急性保健設施、家庭保健和緊急醫療保健。其產品線包括呼吸護理產品、醫療氣體設備和緊急醫療產品。該公司成立於1979年，總部設在密蘇裏州聖路易斯。
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
接受骨生物製品日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收骨生物和相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧